Nichole Tucker, MA, is the Senior Editor for Targeted Oncology and host of the Targeted Talks podcast. Tucker received her Bachelor of Arts in Mass Communications from Virginia State University and her Master of Arts in Media & International Conflict from University College Dublin.
Tazemetostat Results Signal the Utility of Biomarker-Driven Therapy for BAP1-Inactivated MPMJune 24th 2022
Results from a study of tazemetostat in patients with BAP1-inactivated malignant pleural mesothelioma show the feasibility of molecularly-stratified therapy for patients with relapsed or refractory disease.
Utilizing Big Data to Understand Disparities in Cancer Care Across South FloridaJune 23rd 2022
In an interview with Targeted Oncology, Leonard A. Kalman, MD, discussed how real-world data will improve the understanding of patients with cancer being treated at Miami Cancer Institute and of how the business runs overall.
Targeting TRK Family Proteins in Patients With Solid TumorsJune 22nd 2022
Alexander Drilon, MD, discussed NTRK gene fusions in solid tumors, collective findings of studies assessing larotrectinib for the treatment of these fusions, and how to conduct genomic testing to identify patients who might benefit from TRK inhibitor therapy.
Understanding CAR T-Cell Therapy Utilization Patterns in the Community Oncology SettingJune 8th 2022
In an interview with Targeted Oncology™, Bruce Feinberg, DO, discussed the use of CAR T-cell therapy in the community oncology setting, the challenges oncologist face, and the next wave of innovation to improve CAR T-cell administration for patients.
Larotrectinib Exhibits Rapid and Sustained HRQoL Improvement in TRK Fusion CancersJune 7th 2022
Continued robust quality of life improvement documented in an expanded dataset of patients with TRK fusion cancer treated with larotrectinib are consistent with the rapid onset of clinical benefit and favorable safety profile of larotrectinib in both adult and pediatric patients.
Hyper-CVAD With Blinatumomab and Inotuzumab Shows High Efficacy in Ph-Negative B-Cell ALLJune 4th 2022
The probability of minimal residual disease negativity and complete remission in patients who received hyper-CVAD with blinatumomab and inotuzumab is higher compared with hyper-CVAD and blinatumomab alone.
Community Providers Face Hurdles With CAR T-Cell Therapy Referrals and In-Office InfusionJune 3rd 2022
Few community practices are performing in-office infusions on CAR T-cell therapy, but due to interest from 20% of them, experts recommend stakeholder alignment to address the concerns of the oncology population.
Omidubicel Developer Seeks FDA Approval to Treat Blood Cancers in Need of TransplantationJune 3rd 2022
Within 60 days, the FDA will make a decision on whether to accept the biologics license application for omidubicel as treatment for patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.
FDA Grants Fast Track Status to PDS0101 Plus Pembrolizumab for Recurrent/Metastatic HPV16+ HNSCCJune 2nd 2022
A fast track designation has been granted by the FDA to the combination of PDS0101 and pembrolizumab, an investigational regimen for the treatment of patients with recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma.
Active Surveillance Continues to Rise in Low- to Intermediate-Risk Prostate CancerJune 1st 2022
In an interview with Targeted Oncology, William J. Catalona, MD, reviewed the history of active surveillance in the prostate cancer space and how the practice has become more widespread in the United States.
Enzalutamide/ADT Shows Survival Benefit in mHSPC Cohort Previously Treated With Local TherapyMay 30th 2022
In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the use of enzalutamide plus androgen deprivation therapy in metastatic hormone sensitive prostate cancer and how post-hoc findings from the ARCHES study can be applied to practice.
Community Health Systems Test for Recommended Cancer Biomarkers More Often Than Independent PracticesMay 26th 2022
In patients with advanced non-squamous non–small cell lung cancer treated within large community health systems in the United States , biomarker testing appeared to be significantly higher compared with independent community practices, research shows.
More Analyses Explore Benefit of Frontline Maintenance Avelumab Plus BSC in Advanced UCMay 19th 2022
In an interview with Targeted Oncology, Joaquim Bellmunt, MD, PhD, discussed the long-term overall survival data for first-line maintenance avelumab in mUC presented at the AUA 2022 Annual Meeting and a sub-analysis of the JAVELIN Bladder 100 trial being read out at the upcoming 2022 ASCO Annual Meeting.
Darolutamide Continues to Show Strong Efficacy in nmCRPC After 3 Years, Regardless of Prior TherapyMay 14th 2022
Findings from a post-hoc analysis of the phase 3 ARAMIS clinical trial shows positive efficacy and consistent safety and tolerability with darolutamide in patients with nonmetastatic castration resistant prostate cancer, despite type of prior local therapy.
Activity of Ceralasertib With BTK Inhibition in High-Risk R/R CLL Calls to Further InvestigationMay 12th 2022
In an interview with Targeted Oncology, Wojciech Jurczak, MD, PhD, discussed the clinical trial investigation of ceralasertib with or without acalabrutinib in patients with high-risk relapsed or refractory chronic lymphocytic leukemia.